SAN

81.26

+0.58%↑

UCB

266.3

-2.31%↓

SHL.DE

38.44

+0.58%↑

ARGX

712.6

+0.96%↑

VIE

35.24

-0.31%↓

SAN

81.26

+0.58%↑

UCB

266.3

-2.31%↓

SHL.DE

38.44

+0.58%↑

ARGX

712.6

+0.96%↑

VIE

35.24

-0.31%↓

SAN

81.26

+0.58%↑

UCB

266.3

-2.31%↓

SHL.DE

38.44

+0.58%↑

ARGX

712.6

+0.96%↑

VIE

35.24

-0.31%↓

SAN

81.26

+0.58%↑

UCB

266.3

-2.31%↓

SHL.DE

38.44

+0.58%↑

ARGX

712.6

+0.96%↑

VIE

35.24

-0.31%↓

SAN

81.26

+0.58%↑

UCB

266.3

-2.31%↓

SHL.DE

38.44

+0.58%↑

ARGX

712.6

+0.96%↑

VIE

35.24

-0.31%↓

Search

Laboratorios Farmaceuticos Rovi SA

Fermé

SecteurSoins de santé

84.3 -0.71

Résumé

Variation du prix de l'action

24h

Actuel

Min

84

Max

85.85

Chiffres clés

By Trading Economics

Revenu

-33M

43M

Ventes

7.9M

218M

P/E

Moyenne du Secteur

35.869

63.808

BPA

0.834

Marge bénéficiaire

19.539

Employés

1,950

EBITDA

-21M

63M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+3.46% upside

Dividendes

By Dow Jones

Prochains Résultats

6 mai 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

353M

4.3B

Ouverture précédente

85.01

Clôture précédente

84.3

Sentiment de l'Actualité

By Acuity

50%

50%

156 / 348 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

14 avr. 2026, 23:36 UTC

Acquisitions, Fusions, Rachats

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion -- Update

14 avr. 2026, 23:24 UTC

Actions en Tendance

Stocks to Watch: Gloo, Broadcom, GitLab

14 avr. 2026, 22:42 UTC

Acquisitions, Fusions, Rachats

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion

14 avr. 2026, 21:32 UTC

Principaux Mouvements du Marché

GitLab Shares Rise on Expanded Google Cloud Collaboration

14 avr. 2026, 23:54 UTC

Market Talk

Nikkei May Rise as Fears About Energy Shortage Ease -- Market Talk

14 avr. 2026, 23:34 UTC

Market Talk

Gold Edges Lower on Possible Technical Correction -- Market Talk

14 avr. 2026, 22:54 UTC

Résultats

BRP: Amendment Mainly Leads to 25% Tariff on Total Value of Imported Snowmobiles and Majority of ORV Models, Replacing Previous 50% Tariff on Applicable Metal Content Only >DOO.T

14 avr. 2026, 22:54 UTC

Résultats

BRP: Suspending Guidance Following Amendment of Section 232 Tariffs on Steel, Aluminum and Copper Imports Into U.S., Which Came Into Effect on April 6 >DOO.T

14 avr. 2026, 22:54 UTC

Résultats

BRP: Currently Estimates Potential Incremental Tariff Cost Related to This Amendment in Excess of $500M for Remainder of Yr >DOO.T

14 avr. 2026, 22:54 UTC

Résultats

BRP: Suspends FY27 Guidance Due to Changes to U.S. Tariff Environment

14 avr. 2026, 22:17 UTC

Acquisitions, Fusions, Rachats

Yancoal Australia: Targets Deal Completion Toward End of 3Q

14 avr. 2026, 22:17 UTC

Acquisitions, Fusions, Rachats

Yancoal Australia: Acquisition Diversifies Portfolio; Met Coal Share to Rise to 22%

14 avr. 2026, 22:17 UTC

Acquisitions, Fusions, Rachats

Yancoal Australia: Asset 'Strong Strategic Fit'; to Positively Add Production, Cash Flow

14 avr. 2026, 22:16 UTC

Acquisitions, Fusions, Rachats

Yancoal Australia: Intends to Fund Acquisition With Cash, 5-Year Loan Facility

14 avr. 2026, 22:15 UTC

Acquisitions, Fusions, Rachats

Yancoal Australia: Contingent Consideration Linked to Average Annual Prices For 5 Years

14 avr. 2026, 22:14 UTC

Acquisitions, Fusions, Rachats

Yancoal Australia: Deal Includes Contingent Cash Consideration Up to $550 Million

14 avr. 2026, 22:13 UTC

Acquisitions, Fusions, Rachats

Yancoal Australia: Deal Includes $1.85 Billion Upfront Consideration

14 avr. 2026, 22:12 UTC

Acquisitions, Fusions, Rachats

Yancoal Australia: To Buy Kestrel Stake From EMR Capital, Adaro Capital

14 avr. 2026, 22:12 UTC

Acquisitions, Fusions, Rachats

Yancoal Australia: To Buy Kestrel Stake For Up to $2.4 Billion

14 avr. 2026, 22:10 UTC

Acquisitions, Fusions, Rachats

Yancoal Australia: to Acquire 80% Interest in Kestrel Coal Mine

14 avr. 2026, 20:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Basic Materials Roundup: Market Talk

14 avr. 2026, 20:33 UTC

Acquisitions, Fusions, Rachats

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

14 avr. 2026, 20:32 UTC

Actions en Tendance

Stocks to Watch: JPMorgan, American Airlines, LVMH, BlackRock -- WSJ

14 avr. 2026, 19:59 UTC

Acquisitions, Fusions, Rachats

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

14 avr. 2026, 19:38 UTC

Résultats

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14 avr. 2026, 19:27 UTC

Market Talk

U.S. Natural Gas Futures Extend Losing Streak -- Market Talk

14 avr. 2026, 19:21 UTC

Market Talk
Principaux Événements d'Actualité

Oil Futures Retreat on Hopes for U.S.-Iran Peace Talks -- Market Talk

14 avr. 2026, 19:09 UTC

Acquisitions, Fusions, Rachats

Apple and Amazon Partner on Satellite Deal. Why It Makes Sense. -- Barrons.com

14 avr. 2026, 18:30 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14 avr. 2026, 18:30 UTC

Market Talk

Treasury Yields, Dollar Fall as Markets Price Higher Odds of Fed Cuts -- Market Talk

Comparaison

Variation de prix

Laboratorios Farmaceuticos Rovi SA prévision

Objectif de Prix

By TipRanks

3.46% hausse

Prévisions sur 12 Mois

Moyen 86.75 EUR  3.46%

Haut 90 EUR

Bas 83.5 EUR

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

2 ratings

1

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

51.1 / N/ASupport & Résistance

Court Terme

Weak Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

Weak Bearish Evidence

Sentiment

By Acuity

156 / 348Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
help-icon Live chat